Suppr超能文献

人类免疫缺陷病毒蛋白酶抑制剂洛匹那韦和利托那韦的无血清50%抑制浓度的测定。

Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

作者信息

Hickman Dean, Vasavanonda Sudthida, Nequist George, Colletti Lynn, Kati Warren M, Bertz Richard, Hsu Ann, Kempf Dale J

机构信息

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA.

出版信息

Antimicrob Agents Chemother. 2004 Aug;48(8):2911-7. doi: 10.1128/AAC.48.8.2911-2917.2004.

Abstract

Using measured free fraction and 50% inhibitory concentration (IC50) values for the human immunodeficiency virus protease inhibitors lopinavir (LPV) and ritonavir (RTV) in tissue culture media with various protein concentrations ranging from 5 to 50%, we estimated serum-free IC50 values for each drug. The range of serum-free IC50 values (0.64 to 0.77 ng/ml for LPV and 3.0 to 5.0 ng/ml for RTV) did not exhibit a trend with increasing protein concentrations, despite a 10-fold difference in the free fraction value (0.006 to 0.063) for LPV and a 5-fold difference in the free fraction value (0.013 to 0.057) for RTV. The mean serum-free IC50 by the MTT-MT4 assay (0.69 ng/ml for LPV and 4.0 ng/ml for RTV) may be the most accurate parameter for the estimation of the inhibitory quotient (IQ), a relative measure of in vivo potency defined as the ratio of the minimal free drug concentration in plasma (C(trough,free)) for a specific patient population and the serum-free IC50. Using this approach, we calculated the average IQs for protease inhibitor-naïve patients for LPV and RTV to be 67 and 5.6, respectively.

摘要

在蛋白质浓度为5%至50%的各种组织培养基中,利用测得的人免疫缺陷病毒蛋白酶抑制剂洛匹那韦(LPV)和利托那韦(RTV)的游离分数和50%抑制浓度(IC50)值,我们估算了每种药物的无血清IC50值。尽管LPV的游离分数值有10倍差异(0.006至0.063),RTV的游离分数值有5倍差异(0.013至0.057),但无血清IC50值范围(LPV为0.64至0.77 ng/ml,RTV为3.0至5.0 ng/ml)并未随蛋白质浓度增加呈现出一种趋势。通过MTT-MT4测定法得到的平均无血清IC50(LPV为0.69 ng/ml,RTV为4.0 ng/ml)可能是估算抑制商(IQ)的最准确参数,抑制商是体内效价的一种相对度量,定义为特定患者群体血浆中最小游离药物浓度(C(谷值,游离))与无血清IC50的比值。采用这种方法,我们计算出初治蛋白酶抑制剂患者中LPV和RTV的平均IQ分别为67和5.6。

相似文献

9
Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
AIDS Res Hum Retroviruses. 2004 Mar;20(3):275-8. doi: 10.1089/088922204322996509.

引用本文的文献

1
Deriving protein binding-corrected chemical concentrations for in vitro testing.
Clin Transl Sci. 2023 Nov;16(11):2123-2129. doi: 10.1111/cts.13616. Epub 2023 Aug 28.
5
Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):147-57. doi: 10.1002/psp4.12065. Epub 2016 Mar 22.
7
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.
J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8. doi: 10.1097/QAI.0b013e31827fd47e.
8
Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.
Antimicrob Agents Chemother. 2012 Nov;56(11):5938-45. doi: 10.1128/AAC.00691-12. Epub 2012 Sep 10.

本文引用的文献

4
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
AIDS. 2002 Mar 29;16(5):799-800. doi: 10.1097/00002030-200203290-00020.
5
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus.
J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):210-1. doi: 10.1097/00126334-200106010-00018.
6
9
Indinavir plasma protein binding in HIV-1-infected adults.
AIDS. 2000 Oct 20;14(15):2293-7. doi: 10.1097/00002030-200010200-00010.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验